Boston Scientific shows strong profit growth:
This article was originally published in Clinica
Boston Scientific has wiped out its first-half loss with net income of $47 million in the third quarter, up 29% on the previous year. In the first nine months net income was $24.3 million compared with $52.6 million a year earlier. Boston's third-quarter sales were 29% higher at $232.8 million and 28% up at $675.8 million in the first nine months. CEO Pete Nicholas says Boston had "excellent results in both vascular and non-vascular businesses". The three acquisitions this autumn - EP Technologies, Meadox Medicals and Heart Technology - will "further improve Boston's strategic position" in less invasive medicine, Mr Nicholas adds.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.